A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)

A Multi-center Randomized, Double-blind, Placebo Controlled, Parallel-group Study of CD07743 for the Improvement of Lateral Canthal Lines (Crow's Feet)

This double-blind study has two parts for each subject (same population):

Part A: initial treatment in Lateral Canthal Lines (LCL) (placebo-controlled):

• To assess the efficacy and safety of Azzalure® compared to placebo in the improvement of moderate to severe LCLs.
• To assess the subjects' level of satisfaction with the appearance of their LCLs compared to placebo.

Part B: repeated treatment in LCL with or without Glabellar Lines (GL) (active treatment, up to 1 year):

• To assess safety of Azzalure® following repeated administration in the improvement of moderate to severe LCLs.
• To assess the safety of Azzalure® when used concomitantly for improvement of moderate to severe LCLs and GLs.
• To assess the subjects' level of satisfaction with the appearance of their LCLs.

Study Overview

• Status: Completed
• Conditions: Canthal Lines
• Intervention / Treatment: Other: Placebo; Drug: Botulinum Toxin Type A

• Study Type: Interventional
• Enrollment (Actual): 335
• Phase: Phase 3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subjects, 18 to 65 years of age (Screening visit),
• Moderate or severe (grade 2 or 3, Hund 2006) Lateral Canthal Lines "at maximum smile" determined by investigator at screening and baseline
• Mild to severe (grade 1, 2 or 3, Hund 2006) Lateral Canthal Lines "at rest" determined by investigator at screening and baseline
• The subject is a female of childbearing potential and has a negative urine pregnancy test (UPT) at screening and baseline
• Subjects who are not satisfied with their appearance at screening and baseline
• The subject is willing and able to comply with the requirements of the protocol and agree to adhere to the visit schedule, concomitant therapy prohibitions and must be compliant to the study instruction.
• The subject agrees to participate in the study, verified by dating and signing an approved written Informed Consent Form (ICF) and Photography Consent Form (PCF) (selected sites only if applicable) at the enrolment visit before any study procedures at screening

Exclusion Criteria:

• Any prior surgery affecting the orbicularis oculi muscle, prior blepharoplasty or brow lift, or any prior cosmetic procedures or scars that may interfere with the evaluation of the investigator.
• Previous insertion of any permanent, semi-permanent or biodegradable material in the periorbital region or facial treatment with augmentation material (e.g. silicon injections, collagen type implants, hyaluronic acid, lactic acid, etc.) within 12 months prior to screening.
• Any prior treatment with botulinum toxin (of any serotype)
• Previous treatment with lasers for skin resurfacing (e.g. CO2 (carbon dioxide)-laser) or treatment with deep chemical peels and any other esthetic or dermatologic treatments or procedures in any area of the face within 12 months prior to screening.
• Any planned facial cosmetic surgery or procedures during the study period.
• Presence of any bleeding disorders
• Pregnant or lactating women or women who are planning pregnancy during the study.
• Known hypersensitivity to any of the test materials or related compounds.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Botulinum Toxin type A; During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo	Drug: Botulinum Toxin Type A; During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
Placebo Comparator: Placebo; During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo	Other: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Responders on the Severity of Lateral Canthal Lines "at Maximum Smile".	A positive response (responder) is defined as a grade of 0 or 1 (none or mild), as assessed by the investigator.	Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Satisfied With the Appearance of Their Lateral Canthal Lines	Participants were asked to assess their degree of satisfaction with the appearance of their lateral canthal lines using a 4-point scale with the grades Very satisfied, Satisfied, Dissatisfied, and Very dissatisfied. A participant is considered satisfied if he/she answers Very satisfied or Satisfied.	Week 4

Collaborators and Investigators

• Sponsor: Galderma R&D

Study record dates

Study Major Dates

• Study Start: January 1, 2011
• Primary Completion (Actual): May 1, 2012
• Study Completion (Actual): May 1, 2012

Study Registration Dates

• First Submitted: March 2, 2011
• First Submitted That Met QC Criteria: March 2, 2011
• First Posted (Estimate): March 3, 2011

Study Record Updates

• Last Update Posted (Actual): May 1, 2020
• Last Update Submitted That Met QC Criteria: April 21, 2020
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Keywords: Canthal lines
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Cholinergic Agents; Membrane Transport Modulators; Acetylcholine Release Inhibitors; Neuromuscular Agents; Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA
• Other Study ID Numbers: RD.03.SPR.40131

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO